Mirae Asset Global Investments Co. Ltd. Sells 121 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 7.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,615 shares of the company’s stock after selling 121 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Axsome Therapeutics were worth $140,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after purchasing an additional 27,534 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $1,052,000. Pallas Capital Advisors LLC bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at about $2,237,000. Captrust Financial Advisors acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $514,000. Finally, BNP Paribas Financial Markets raised its position in shares of Axsome Therapeutics by 71.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after acquiring an additional 5,737 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Truist Financial upped their target price on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Leerink Partners upped their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a report on Monday. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. Finally, StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $147.13.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $131.68 on Friday. The firm’s 50 day moving average is $96.55 and its 200-day moving average is $92.67. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $6.38 billion, a PE ratio of -20.17 and a beta of 1.05. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the previous year, the business earned ($1.32) EPS. Equities research analysts anticipate that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.